A Phase I, Open-label Dose Escalation Study With Safety Expansion of TAS266 Administered by IV Infusion to Patients With Advanced Solid Tumors
Interventional
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Frequency and characteristics of Dose limiting toxicities at each dose level
2 years
Yes
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals
United States: Food and Drug Administration
CTAS266X2101
NCT01529307
June 2012
September 2012
Name | Location |
---|---|
H. Lee Moffitt Cancer Center/University of South Florida Moffitt SC | Tampa, Florida 33612 |
University of Utah / Huntsman Cancer Institute Huntsman UT | Salt Lake City, Utah 84103 |
South Texas Accelerated Research Therapeutics START | San Antonio, Texas 789229 |